While more studies are clearly needed to further define how MARCH5 loss (or MCL1 amplification) alters responsiveness to BH3 mimetics, this study indicates that MARCH5 loss, which appears to be relatively common in PCa, confers vulnerabilities to BH3 mimetic drugs. The gene discussed is MCL1; the disease is posterior cortical atrophy.